Siemens Recalls MicroScan Synergies plus® and rapID/S plus Gram Negative Panels

Siemens Recalls MicroScan Synergies plus® and rapID/S plus Gram Negative Panels

  • Siemens recalls specific panels shipped June 2011 through August 2013

TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Siemens Healthcare Diagnostics (NYS: SI) has issued a voluntary recall of its MicroScan Synergies plus® Negative and rapID/S plus Negative panels. These panels are used for determining antimicrobial susceptibility and/or identification for gram-negative bacteria. An internal investigation has confirmed an increase in false susceptible and false intermediate misreads for imipenem and/or meropenem when read rapidly (< 16 hours) on the MicroScan® WalkAway Microbiology System¹. The investigation determined that no other antimicrobial agent results are affected. Siemens has notified the FDA of this action.

This defect could potentially lead to misclassification of a resistant or partially resistant strain of gram negative bacteria which may result in treatment with an inappropriate antibiotic or a delay in initiating appropriate therapy. As a result of these findings, Siemens has issued a voluntarily recall for MicroScan Synergies plus Negative and rapID/S plus Negative panels shipped from June 2011 through August 2013. This issue is not panel lot specific or related to a particular WalkAway instrument model. Dried Overnight Gram Negative Panels are not impacted by the issue.


The following panels have been affected by this issue:

Description  Siemens Material Number (SMN)  Part Number  Distribution
Neg Combo Panel Type 2 (SI+NC2)  10444747  B1025-108  Brazil, China, Colombia. Germany, India, Mexico, Peru, Russia, South Africa, Thailand, United States
Neg/Urine Combo Panel Type 1 (SI+NUC1)  10444745  B1025-106  Canada, China, Colombia, United States
Neg/Urine Combo Panel Type 2 (SI+NUC2)  10444749  B1025-112  Algeria, Brazil, Colombia, Italy, Mexico, Romania, Russia, Spain, United States
Neg/Urine Combo Panel Type 5 (SI+NUC5)  10483101  B1025-115  United States
Neg Breakpoint Combo Panel Type 7 (SI+NBPC7)  10444748  B1025-109  Algeria, India, Iraq, Kazakhstan, Malaysia, Mexico, Oman, Poland, Qatar, Romania, Russia, Saudi Arabia, Spain, Thailand Turkey, United Arab Emirates, United States, Uruguay
Neg Combo Panel Type 3 (SI+NC3)  10444600  B1016-201  None*
Neg/Urine Combo Panel Type 4 (SI+NUC4)  10444601  B1016-202  None*
Neg Breakpoint Combo Panel Type 8 (SI+NBPC8)  10460272  B1016-203  Austria, Germany Romania
Neg Combo Type 3.11 (R+NC3.11)  10444792  J1025-311  Japan
Neg Combo Type 3.12 (R+NC3.12)  10444793  J1025-312  Japan
Neg MIC Type 3.33 (R+NC3.33)  10444794  J1025-333  Japan

* Products are make to order and none were ordered during the recall period.

 

All affected customers have already been notified and instructed, via letter and the addition of Important Product Information (IPI) labeling to the panel boxes, to suppress all Susceptible (S) or Intermediate (I) interpretation and MIC results for imipenem and meropenem with all Synergies plus Negative and rapID/S plus Negative panels, until further notice.

Siemens Healthcare Diagnostics has also recommended that customers consider reviewing previous Synergies plus Negative and rapID/S plus Negative test results from June 2011 through August 2013, conduct patient follow-up, and/or repeat imipenem and/or meropenem susceptibility testing by another product or method, if the isolates are still available.

Customers with questions may contact Siemens Healthcare Diagnostics via telephone at 1-800-677-7226, Option 1 (USA/Canada), Mondays - Fridays 7:00 am - 7:00 pm (EST) and Saturdays, Sundays and holidays 7:30 am - 4:00 pm (EST).

¹ Editor's note: Product names are specific and should not be abbreviated or shortened.

The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source - from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2012 (to September 30), the Sector posted revenue of 13.6 billion euros and profit of around 1.8 billion euros. For further information please visit: www.siemens.com/healthcare.



Siemens Healthcare Diagnostics
Susan Drew, 914-524-2844
susan.drew@siemens.com
Follow us on Twitter at: www.twitter.com/siemenshealth

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:

The article Siemens Recalls MicroScan Synergies plus® and rapID/S plus Gram Negative Panels originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.